Management holds a virtual meeting on topline efficacy and safety data from the Phase 2 Study evaluating NDV-01 for treatment of HG-NMIBC on April 28 at 4:30 pm. Webcast Link
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLMD:
- Relmada Therapeutics: Hold Rating Amid Uncertainty and Strategic Shifts
- Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress
- Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress
- Relmada Therapeutics reports Q4 EPS (62c) vs. (84c) last year
- Relmada Therapeutics Secures Exclusive License for NDV-01